$494 Million is the total value of Ghost Tree Capital, LLC's 53 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RYTM | Exit | RHYTHM PHARMACEUTICALS INC | $0 | – | -25,000 | -100.0% | -0.17% | – |
| FXB | Exit | CURRENCYSHS BRIT POUND STERbrit pound ste | $0 | – | -9,100 | -100.0% | -0.28% | – |
| EDIT | Exit | EDITAS MEDICINE INC | $0 | – | -65,000 | -100.0% | -0.47% | – |
| GNMK | Exit | GENMARK DIAGNOSTICS INC | $0 | – | -500,000 | -100.0% | -0.49% | – |
| ABLX | Exit | ABLYNX NVsponsored adr | $0 | – | -90,000 | -100.0% | -0.53% | – |
| DERM | Exit | DERMIRA INC | $0 | – | -100,000 | -100.0% | -0.65% | – |
| RIGL | Exit | RIGEL PHARMACEUTICALS INC | $0 | – | -825,000 | -100.0% | -0.75% | – |
| NTLA | Exit | INTELLIA THERAPEUTICS INC | $0 | – | -175,000 | -100.0% | -0.79% | – |
| ITEK | Exit | INOTEK PHARMACEUTICALS CORP | $0 | – | -1,300,000 | -100.0% | -0.80% | – |
| CRSP | Exit | CRISPR THERAPEUTICS AGnamen akt | $0 | – | -150,000 | -100.0% | -0.83% | – |
| IRTC | Exit | IRHYTHM TECHNOLOGIES INC | $0 | – | -65,000 | -100.0% | -0.85% | – |
| INCY | Exit | INCYTE CORP | $0 | – | -50,000 | -100.0% | -1.11% | – |
| HZNP | Exit | HORIZON PHARMA PLC | $0 | – | -400,000 | -100.0% | -1.37% | – |
| AIMT | Exit | AIMMUNE THERAPEUTICS INC | $0 | – | -158,200 | -100.0% | -1.40% | – |
| ARRY | Exit | ARRAY BIOPHARMA INC | $0 | – | -500,000 | -100.0% | -1.50% | – |
| LJPC | Exit | LA JOLLA PHARMACEUTICAL CO | $0 | – | -200,000 | -100.0% | -1.51% | – |
| JUNO | Exit | JUNO THERAPEUTICS INC | $0 | – | -150,000 | -100.0% | -1.61% | – |
| SAGE | Exit | SAGE THERAPEUTICS INCput | $0 | – | -43,700 | -100.0% | -1.69% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -180,000 | -100.0% | -1.69% | – |
| XLRN | Exit | ACCELERON PHARMA INC | $0 | – | -200,000 | -100.0% | -1.99% | – |
| BMY | Exit | BRISTOL MYERS SQUIBB COcall | $0 | – | -150,000 | -100.0% | -2.16% | – |
| PTLA | Exit | PORTOLA PHARMACEUTICALS INC | $0 | – | -225,000 | -100.0% | -2.57% | – |
| AGN | Exit | ALLERGAN PLCcall | $0 | – | -75,000 | -100.0% | -2.88% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -325,000 | -100.0% | -3.00% | – |
| ALXN | Exit | ALEXION PHARMACEUTICALS INC | $0 | – | -115,000 | -100.0% | -3.22% | – |
| ESPR | Exit | ESPERION THERAPEUTICS INC NE | $0 | – | -230,000 | -100.0% | -3.55% | – |
| CELG | Exit | CELGENE CORPcall | $0 | – | -150,000 | -100.0% | -3.67% | – |
| IMMU | Exit | IMMUNOMEDICS INCcall | $0 | – | -1,300,000 | -100.0% | -4.93% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 30 | Q3 2023 | 7.3% |
| ASCENDIS PHARMA A/S - ADR | 28 | Q3 2023 | 11.8% |
| BIOCRYST PHARMACEUTICALS INC | 25 | Q2 2023 | 2.4% |
| AMICUS THERAPEUTICS INC | 23 | Q3 2023 | 5.6% |
| SAREPTA THERAPEUTICS INC | 22 | Q3 2023 | 9.1% |
| SPDR SER TR | 20 | Q3 2022 | 16.9% |
| IOVANCE BIOTHERAPEUTICS INC | 18 | Q2 2023 | 5.5% |
| ROCKET PHARMACEUTICALS INC | 18 | Q2 2023 | 6.1% |
| SAGE THERAPEUTICS INC | 18 | Q1 2021 | 4.8% |
| IMMUNOMEDICS INC | 17 | Q2 2020 | 8.7% |
View Ghost Tree Capital, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-16 |
View Ghost Tree Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.